Biosimilar Sponsors: We Need To Do A Better Job Educating Physicians And Patients
Mylan's Chrys Kokino says failure of sponsors to educate "really is a huge miss on our part."
You may also be interested in...
Misinformation Contributing To Slower Biosimilar Uptake, Execs Claim
Dispelling myths around biosimilar efficacy and safety may be crucial to driving uptake of biosimilars, executives from Sandoz and Boehringer Ingelheim have argued in an opinion piece in the journal, BioDrugs, as they asserted it was the “responsibility of all stakeholders to challenge biosimilar disparagement and misinformation when encountered.”
Gottlieb Shifts From Regulatory To Reimbursement Focus In One Of First Post-Commissioner Appearances
CAR-T reimbursement is concern for former US FDA commissioner Scott Gottlieb in speech at the National Press Club.
Biosimilars: Is Small Dip In Development Indicative Of Sustained Downward Trend?
As US FDA sees dip in application development, experts offer contrasting assessments about future of biosimilars at AAM's GRx Biosims conference.